Cargando…

The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study

This study investigated the impact of retinal fluid tolerance on retinal thickness and visual acuity in patients with neovascular age-related macular degeneration after 18 months of treatment using intravitreal aflibercept. This retrospective study was based on the medical records of 90 eyes present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeng, Yu-Ting, Lai, Tso-Ting, Lin, Chao-Wen, Chen, Ta-Ching, Hsieh, Yi-Ting, Lin, Chang-Ping, Ho, Tzyy-Chang, Yang, Chung-May, Yang, Chang-Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333245/ https://www.ncbi.nlm.nih.gov/pubmed/35900984 http://dx.doi.org/10.1371/journal.pone.0271999

Ejemplares similares

Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study
por: Lai, Tso-Ting, et al.
Publicado: (2019)

Combined quantitative and qualitative optical coherence tomography angiography biomarkers for predicting active neovascular age-related macular degeneration
por: Hsu, Cherng-Ru, et al.
Publicado: (2021)

Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
por: Yildiz, Dilan, et al.
Publicado: (2021)

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease
por: Hsia, Ning-Yi, et al.
Publicado: (2021)

Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study
por: Lai, Tso-Ting, et al.
Publicado: (2022)

Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
por: Ma, I-Hsin, et al.
Publicado: (2021)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Clinical characteristics and long-term evolution of lamellar macular hole in high myopia
por: Hsia, Yun, et al.
Publicado: (2020)

Baseline predictors for good visual gains after anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization
por: Hsu, Cherng-Ru, et al.
Publicado: (2022)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
por: Ali Said, Yasmin, et al.
Publicado: (2022)

Long-Term Change in Renal Function After Intravitreal Anti-VEGF Treatment for Diabetic Macular Edema: A 2-Year Retrospective Cohort Study
por: Fang, Yi-Chung, et al.
Publicado: (2023)

Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy
por: Huang, Chu-Hsuan, et al.
Publicado: (2021)

Full-thickness macular hole formation in proliferative diabetic retinopathy
por: Tsui, Mei-Chi, et al.
Publicado: (2021)

Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept
por: Sato, Tomohito, et al.
Publicado: (2021)

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
por: Thomas, Michael, et al.
Publicado: (2013)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg, Justus G
Publicado: (2019)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Metabolic Syndromes as Important Comorbidities in Patients of Inherited Retinal Degenerations: Experiences from the Nationwide Health Database and a Large Hospital-Based Cohort
por: Chiou, Guann-Jye, et al.
Publicado: (2021)

HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: You, Qi Sheng, et al.
Publicado: (2018)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Wang, Jia-Kang, et al.
Publicado: (2018)

The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration
por: Kovacs, Attila, et al.
Publicado: (2018)

Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept
por: Wons, Juliana, et al.
Publicado: (2017)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
por: Spooner, Kimberly, et al.
Publicado: (2017)

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
por: Liberski, Sławomir, et al.
Publicado: (2022)

Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Gharbiya, Magda, et al.
Publicado: (2014)

Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
por: Nishikawa, Keiichi, et al.
Publicado: (2019)

Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
por: Itagaki, Kanako, et al.
Publicado: (2020)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

Efficacy of Aflibercept as initial treatment for neovascular age-related macular degeneration in an Iraqi patient sample
por: Hussein, Zaid Rajab, et al.
Publicado: (2023)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B
Publicado: (2023)

Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan
por: Lo, Kang-Jung, et al.
Publicado: (2020)

RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: Kaiser, Peter K., et al.
Publicado: (2021)

Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases
por: Sophie, Raafay, et al.
Publicado: (2012)

Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab
por: Cao, Xuan, et al.
Publicado: (2023)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
por: Balaratnasingam, Chandrakumar, et al.
Publicado: (2015)

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
por: Parvin, Parmis, et al.
Publicado: (2017)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
por: Elfandi, Sufian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5mqdopv3d708khicv8gvf7hl86